drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A KLK2×CD3 T-cell–redirecting bispecific antibody that binds KLK2 on prostate tumor cells and CD3 on T cells to trigger TCR-mediated cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific antibody that binds KLK2 on prostate tumor cells and CD3 on T cells, redirecting T cells to form an immune synapse and induce TCR-mediated activation and cytotoxic lysis of KLK2-expressing cancer cells.
drug_name
JNJ-78278343 (pasritamig)
nct_id_drug_ref
NCT06095089